The potent COVID-19 vaccine developed by Pfizer Inc. and BioNTech SE is widely used in the U.S. and Europe, but China has yet to approve the shot, leaving questions about Beijing’s plans for an inoculation that’s heavily coveted in the rest of the world.
Regulators on China’s mainland haven’t signed off on the vaccine nearly nine months after it received its first regulatory clearance in the U.K.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.